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Abstract
Background: Molecular genetic studies on rare tumour entities, such as bone tumours, often require the use of
decalcified, formalin-fixed, paraffin-embedded tissue (dFFPE) samples. Regardless of which decalcification procedure
is used, this introduces a vast breakdown of DNA that precludes the possibility of further molecular genetic testing.
We set out to establish a robust protocol that would overcome these intrinsic hurdles for bone tumour research.
Findings: The goal of our study was to establish a protocol, using a modified DNA isolation procedure and quality
controls, to select decalcified samples suitable for array-CGH testing. Archival paraffin blocks were obtained from 9
different pathology departments throughout Europe, using different fixation, embedding and decalcification
procedures, in order to preclude a bias for certain lab protocols. Isolated DNA samples were subjected to direct
chemical labelling and enzymatic labelling systems and were hybridised on a high resolution oligonucleotide chip
containing 44,000 reporter elements.
Genomic alterations (gains and losses) were readily detected in most of the samples analysed. For example, both
homozygous deletions of 0.6 Mb and high level of amplifications of 0.7 Mb were identified.
Conclusions: We established a robust protocol for molecular genetic testing of dFFPE derived DNA, irrespective of
fixation, decalcification or sample type used. This approach may greatly facilitate further genetic testing on rare
tumour entities where archival decalcified, formalin fixed samples are the only source.
Background
The introduction of high-throughput, high-resolution
molecular screening tools had tremendous impact on
molecular genetic studies both for constitutional and
tumour genetic investigations [1,2]. Whilst the accessi-
bility of good quality samples for constitutional genetic
studies is often achievable, for cancer genetic investiga-
tions it has remained a hurdle especially for those deal-
ing with rare tumour entities. A comprehensive study of
rare cancers, such as bone tumours, requires the use of
archived tissue materials such as formalin fixed paraffin
embedded tissue (FFPE) [3-5]. It is well known that the
quality of FPPE-derived DNA is both fixation time- and
fixative-dependent and is highly variable between differ-
ent institutions. 10% buffered formalin is a commonly
used fixative in routine diagnostic labs. Long term sto-
rage of this fixative leads to the formation of formic
acid and methanol by the Cannizzaro-reaction. Formic
acid promotes the breakdown of the DNA and thus
inferior quality of DNA is extracted from these tissue
samples. To process bone derived tumour samples, an
extra decalcification step is necessary to remove the Ca2+-
containing matrix part of the tissue. This can be achieved
either by EDTA treatment or by an extensive formic acid
treatment. EDTA treatment is a labour-intensive proce-
dure and takes up to several weeks of incubation. The
treatment introduces limited breakdown of DNA but
because of its lengthy procedure it is impractical for
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routine diagnostics. The formic acid-based decalcification
procedure introduces a tremendous breakdown of DNA
within these samples. As a result, most of these samples
are usually regarded as unsuited for molecular biological
testing. The formic acid-based decalcification has been the
gold standard procedure at many institutions, meaning
that most of the archival material collected from multiple
sources has been treated in this way. The goal of our study
was to establish a modified DNA isolation protocol with
quality controls enabling array-CGH testing on decalcified
samples irrespective of fixation and decalcification steps
used. Isolated DNA samples were labelled using two FFPE
labelling kit systems and were hybridised on a high resolu-




Samples were selected for molecular cytogenetic testing
from various partner institutions within the EuroBoNet
consortium http://www.eurobonet.eu for different pro-
jects (rare chondrosarcoma subtypes of bone and pri-
mary angiosarcoma of bone) dealing with decalcified
FFPE (dFFPE) samples. Samples used in this study
represent both tumours with high cellularity and a low
extracellular matrix proportion as well as samples with
low cellularity and an excessive extracellular matrix
composition. Sample collection dates varied from 1990
until 2008. Samples were all fixed in 10% buffered for-
malin but the exact fixation times and conditions are
not known (Table 1).
For one case (Nr 10) array comparison using DNA
isolated from dFFPE tissue and the corresponding frozen
tissue part was possible.
All samples were handled in a coded fashion, and all
procedures were performed according to the ethical
guidelines, ‘’Code for Proper Secondary Use of Human
Tissue in the Netherlands’’ (Dutch Federation of Medi-
cal Scientific Societies).
DNA isolation
Five to ten 0.2 mm FFPE punches or two to five 20 μm
thick dFFPE sections were collected depending on tissue
type and tumour content. From each block a 4 μm con-
secutive section was cut and stained using standard hae-
matoxylin and eosin (HE) staining to visualise target
cells and served as control. An optimized DNA isolation
protocol was developed based on the use of Macherey-
Nagel Nucleospin Tissue kit. Briefly, sections/punches
were collected into an Eppendorf tube and were depar-
affinised using two cycles of xylene incubation, 15 min
each at room temperature, followed by two steps of
100% ethanol incubation, 15 min each. Samples were
then dried and 200 μl PK1 buffer supplemented with
Proteinase K (0.4 mg/ml) was added to each tube and
incubated for 18 hours at 56 °C. On day two, 200 μl
buffer B3 was added to each vial. Samples were vortexed
vigorously, incubated at 70°C for 10 min and vortexed
again. By these means, most tissue pieces were dis-
solved. When visible particles were left (typically bone
remnants), samples were centrifuged for 5 min at 11.000 ×
g and supernatant was transferred to a new tube. Before
loading samples to a DNA binding column, 210 μl 100%
ethanol was added. At this step, a partial precipitation
within the solution was observed in some of the samples.
For DNA binding, samples were centrifuged for 1 min at
11.000 × g. In some cases, repeated centrifugation steps
were necessary. Flow-through was discarded and columns
were washed by adding 500 μl BW solution followed by
1 min 11.000 × g centrifugation step, followed by a second
wash step using 600 μl B5 buffer and centrifugation. To
elute the DNA 50 μl preheated (70°C) MQ solution was
added to the column and incubated at room temperature
for 5 min followed by a centrifugation step at 11000 × g
for 1 min.
DNA isolation from frozen tissue was performed as
described earlier [6].
Sample assessment
DNA concentrations were measured using a Nanodrop
ND-1000 spectrophotometer and 500 ng was electro-
phoresed in a 1% agarose gel stained with ethidium
bromide.
Sample labelling
Agilent Oligo aCGH Labeling Kit for FFPE Samples (Agilent)
utilising ULS labelling system
Labelling was done according to the manufacturer’s
recommendations with some modifications. In brief,
for 44k Agilent arrays (Agilent Technologies, Santa
Clara, CA), 500 ng DNA was chemically labelled with
Universal Linkage System (ULS) Cy3 (test) or Cy5
(reference)-dyes. Before labelling, reference samples
were heat fragmented in order to achieve equal frag-
ment sizes in both test and reference sample. The
labelled samples were then purified using the Agilent
KREApure columns. Labelling efficiency was calculated
using a Nanodrop Spectrophotometer measuring A260
(DNA), A550 (Cy3) and A649 (Cy5).
BioPrime Total FFPE Genomic Labelling System (Invitrogen)
Labelling was done according to the manufacturer’s
recommendations with some modifications. In brief, 500
ng DNA was used for labelling, instead of the recom-
mended 1 μg DNA. Labelling with both 150 ng and 500 ng
DNA was done for one sample (Nr 13). Random prime
(RP) labelling was done by using the BioPrime Total
FFPE Genomic Labelling System (Invitrogen Corpora-
tion, Carlsbad, CA) Labelling efficiency was calculated
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using a Nanodrop Spectrophotometer measuring A260
(DNA), A550 (Cy3) and A649 (Cy5). Heat-fragmented
DNA from a commercial source (Promega Corporation,
Madison, WI) was used as a reference. Samples were
labelled with Alexa Fluor 3 mix (test sample) and Alexa
Fluor 5 mix (reference sample).
For both ULS- and RP-system-labelled test and refer-
ence samples were mixed and hybridized as a gender
mismatch to show dynamic range of hybridisation on
the X and Y chromosomes. Two samples were labelled
both with the random prime kit and with ULS (Nr 10
and Nr 18).
Hybridisation, scanning and, data extraction
Hybridisation was performed on a 4 × 44k Agilent oligo
array Chip at 65°C for 40 hours. Slides were washed with
Oligo aCGH Wash Buffer 1 at room temperature for
5 min followed by a 1 min wash with Oligo aCGH Wash
Buffer 2 at 37°C. Finally, slides were dried without using
the stabilisation and drying solution. Slides were scanned
using an Agilent Scanner with 5 μm scan resolution.
Scan images were processed with Feature Extraction
Software and Genomic Workbench (Agilent Technolo-
gies, Santa Clara, CA). All samples, irrespective of quality,
were processed for further comparisons.
Table 1 Overview of samples included in this study
Sample ID Diagnosis Collection date Material Cellularity Extracellular matrix Decalcification
1 Rare chondrosarcoma 2004 dFFPE High Low Formic acid
2 Rare chondrosarcoma 2007 dFFPE High Low Formic acid
3 Rare chondrosarcoma 2007 dFFPE Low High Formic acid
4 Rare chondrosarcoma 1996 dFFPE Low High Formic acid
5 Rare chondrosarcoma 1997 dFFPE High Low Formic acid
6 Rare chondrosarcoma 2005 dFFPE Low High Formic acid
7 Rare chondrosarcoma 2005 dFFPE High Low Formic acid
8 Rare chondrosarcoma 2004 dFFPE Moderate Moderate Formic acid
9 Rare chondrosarcoma 2006 dFFPE Moderate Moderate Formic acid
10 Rare chondrosarcoma 2000 dFFPE Moderate Moderate Formic acid
11 Rare chondrosarcoma 1996 dFFPE Moderate Moderate Formic acid
12 Rare chondrosarcoma NA dFFPE High Moderate Formic acid
13 Rare chondrosarcoma NA dFFPE High Moderate Formic acid
14 Rare chondrosarcoma 1994 dFFPE High Moderate Formic acid
15 Rare chondrosarcoma NA dFFPE High Moderate Formic acid
16 Rare chondrosarcoma 2007 dFFPE High Moderate Formic acid
17 Rare chondrosarcoma NA dFFPE High Moderate Formic acid
18 Rare chondrosarcoma 2001 dFFPE High Moderate Formic acid
19 Rare chondrosarcoma 1994 dFFPE High Moderate Formic acid
20 Rare chondrosarcoma 1996 dFFPE High Moderate Formic acid
21* Rare chondrosarcoma 2000 Frozen Moderate Moderate None
22** Rare chondrosarcoma 1996 Frozen Moderate Moderate None
23 Chondrosarcoma 2001 Frozen High High None
24 Chondrosarcoma 2003 Frozen low High None
25 Primary angiosarcoma 2007 Frozen High Low None
26 Primary angiosarcoma NA dFFPE High Low Formic acid
27 Primary angiosarcoma 2007 dFFPE High Low Formic acid
28 Primary angiosarcoma 2007 FFPE High Low None
29 Primary angiosarcoma NA FFPE High Low None
30 Primary angiosarcoma 2007 FFPE High Low None
31 Primary angiosarcoma NA dFFPE High Low Formic acid
32 Chondrosarcoma 1990 dFFPE Low High Formic acid
* Corresponding frozen sample Nr 10.
** Corresponding frozen sample Nr 11.
***NA: not available.
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Interphase FISH confirmation
To confirm one of the array-CGH results of case Nr 26,
a two-colour interphase FISH experiment was done.
A BAC-clone (RP1-80K22) located at 8q24.21 covering
the MYC gene locus (detected in red) in combination
with an alpha satellite probe specific to the centromeric
region of chromosome 8 (detected in green) were used
as described earlier [7].
Statistical analysis
Log2 transformed ratio values were extracted from the
scan images and processed using the Feature Extraction
Software package and Genomic Workbench (Agilent).
The exported log2 transformed ratio values were used
for further comparison. Correlations were calculated
using Pearson coefficients and systematic bias calcula-
tions were done by using Bland-Altman plots using the
SPSS 16.0 for Windows software package. For the
Bland-Altman plots the differences between the two
individual reporters measured by two experiments on
the y axis were plotted against the mean log2 ratio of
the two on the x axis. This test allows the investigation
of systematic bias. Relatively small differences and little
bias are represented by a “flat profile”. For the compari-
son of the resulting array-CGH profiles we used the
CGHCall R script developed by van de Wiel et al. [8].
Results
DNA quality and quantity assessment
DNA concentration was estimated using the Nanodrop
system and equal amounts of DNA were electrophoresed
in a 1% agarose gel. The absorption based measurement
using the Nanodrop system showed inconsistent results
when values were compared to agarose gel images. Figure 1
shows a diverse range of DNA fragment sizes for all sam-
ples. Samples with moderate (for example nr 3 and 27) to
severe (sample nr 17, and 31) DNA degradation showed
acceptable CGH profiles. In general, DNA concentration
was overestimated particularly for cartilaginous tumour
samples with high extracellular matrix composition. In
these cases relatively low concentrations were measured
(typically in the range of 2-15 ng/μl) (Table 2) but deter-
mining the concentration based on the corresponding gel
image suggested that these measurements were an over
estimate (Figure 1) (for example: samples nr 9, 11, 15 and
18). As for all labelling reactions, the initial amount of
starting material is a crucial factor. We corrected the
DNA concentration measured by Nanodrop using the
integral of the UV-excited ethidium bromide fluores-
cence obtained from the agarose gel images. For these
measurements, known amounts of reference DNA sam-
ples were loaded. The correction factor between the two
types of measurements, especially at the lower concentra-
tion range, was as high as 10 fold resulting in significant
over estimation of sample concentration for labelling and
consecutive testing.
Comparison of different labelling approaches
Different comparisons were made based on the type of
samples available. A three-way comparison was made
for Nr 10 with DNA collected from both frozen and
dFFPE material. DNA from frozen tissue was labelled
using a random primer labelling kit and DNA from
dFFPE tissue was labelled with both the random primer
labelling kit designed for FFPE samples and ULS label-
ling kit for FFPE samples (Figure 2A, Figure 3). The dif-
ferent labelling schemes showed an overall good
correlation, the Pearson correlation coefficient varied
between 0.542 and 0.682 and showed a better
Figure 1 Quality and quantity assessment of DNA samples:
Image of a 1% agarose gel separation after ethidium bromide
staining depicting several representative tumour samples for
testing. L1 and L2 represent 1 kb+ and 50 bp ladders, respectively.
C1, C2, C3 are high molecular weight genomic DNA samples with
known concentrations of 500, 250 and 50 ng, respectively. Detailed
sample characteristics are provided in Table 2.
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correlation between the ULS-FFPE vs RP frozen (0.682)
than the RP frozen vs RP-FFPE reaction (0.542). Very
good agreement was observed between the two different
labelling reactions using dFFPE samples (0.669). Side-
by-side comparative whole genome overview of the
array-CGH results showed the variation of the reporter
signals was highest (black dots represent individual
reporter elements) in the case of FFPE-RP labelling,
followed by FFPE-ULS and Fr-RP. In all three profiles
almost identical aberrations were present (see Table 3 for
an overview of the genome-wide genomic aberrations).
Since for routine applications the amount of DNA for
testing is often limited, we compared the influence of
lower amounts of starting material for labelling using
500 ng and 150 ng dFFPE-isolated DNA for the FFPE-
RP kit (Nr 13). These results were compared to ULS














1 131.0 1.84 2.47 134.5 0.97 OK
2 153.0 1.84 2.42 130.7 1.17 OK
3 31.9 1.88 2.67 24.9 1.28 OK
4 10.9 1.66 0.41 4.5 2.41 NP
5 13.6 2.08 1.57 3.9 3.51 NP
6 44.7 1.8 1.38 20.5 2.18 NP
7 9.8 2.06 1.92 9.0 1.08 NP
8 44.0 1.1 0.3 3.1 14.36 NP
9 57.5 1.57 0.82 3.8 14.94 Poor
10 540.0 1.78 1.9 346.9 1.56 OK
11 164.0 1.63 1.24 19.5 8.42 Poor
12 102.0 1.76 1.98 19.3 5.27 OK
13 485.0 1.84 2.34 270.5 1.79 OK
14 291.0 1.8 2.3 127.8 2.28 OK
15 430.0 1.69 2.17 76.3 5.64 Poor
16 208.0 1.81 2.21 135.9 1.53 OK
17 269.0 1.84 2.35 192.3 1.40 OK
18 63.0 1.73 2.11 9.7 6.48 Poor
19 215.0 1.75 2.12 146.6 1.47 OK
20 285.0 1.7 2.37 170.4 1.67 OK
21 1376.0 1.78 1.28 565.6 2.43 OK
22 88.6 1.67 0.91 68.1 1.30 OK
23 259.8 1.8 1.75 286.8 0.91 OK
24 496.4 1.7 1.8 523.9 0.95 OK
25 30.6 1.7 1.6 25.2 1.22 NP
26 172.0 1.8 2.11 NP NP OK
27 306.0 1.75 1.98 NP NP OK
28 203.0 1.89 2.31 NP NP OK
29 132.9 1.78 2.05 NP NP OK
30 300.0 1.8 1.96 NP NP OK
31 71.0 1.67 0.89 NP NP OK
32 47.5 1.71 0.68 NP NP Poor
C1 500 1.8 1.95 462.9 1.08 NP
C2 250 1.8 1.95 238 1.05 NP
C3 50 1.8 1.95 45 1.11 NP
* Sample ID corresponds to the sample label in Figure 1.
** Nanodrop concentration/Gel-based concentration.
*** NP: Not performed.
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Figure 2 Array-CGH plots of decalcified FFPE samples after ULS or RP labelling. For all plots: Upper right: Correlation plots of log2 ratios
for each reporter between experiments, with linear regression and Pearson’s correlation coefficients given. Lower left: Bland-Altman plots of the
differences between two reporters measured by two experiments on the y axis against the mean log2 ratio of the two on the x axis. A:
Correlation plots of sample Nr 10 comparing hybridisation of random prime and ULS based labelling of FFPE and RP labelling of frozen tissue
derived DNA samples. B: Correlation plots of sample Nr 13 using FFPE isolated DNA samples with ULS, 150 ng RP and 500 ng RP labelling. C, D
Correlation plots of samples Nr 2 and Nr 17 using FFPE isolated DNA samples with ULS or RP labelling reactions. E: Correlation plot of sample Nr
18. This sample showed a great degree of discrepancy for the estimated DNA concentration between the absorption based and the gel based
measurements.
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Figure 3 Side-by-side comparative whole genome overview of the array-CGH results from case Nr 10. A: Array CGH profile of FFPE tissue
isolated DNA sample after ULS labelling (FFPE-ULS). B: Array CGH profile of FFPE tissue isolated DNA sample after using a Random Primer
labelling especially designed to label FFPE samples (FFPE-RP). C: Array-CGH profile of frozen tissue isolated DNA after standard Random Prime
Labelling reaction (Fr-RP). Normalized log2-ratios are plotted with the scale on the right axis. Vertical bars indicate loss and gain probabilities.
Probability scale is on the left axis; reversed (’1-’) for the gains. Segments are plotted as horizontal blue lines. Segments with a bar extending
beyond the middle axis (probability >0.5) are called as gain or losses. All plots were generated using the CGHCall R software package. The
variation of the reporter signals was the highest (black dots represent individual reporter elements) in case of FFPE-RP labelling (see also Figures
2a) followed by FFPE-ULS and Fr-RP. In all three profiles almost identical calls were present (see Table 3 for details on the called regions).
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labelling reaction using 500 ng of DNA (Figure 2B).
Based on the comparison of the overall profiles, the best
correlation was observed between the two FFPE-RP
reactions (0.873) using different input for labelling (150
vs 500 ng dFFPE DNA for FFPE-RP kit) followed by a
0.694 between the 500 ng FFPE-ULS and 150 ng FFPE-
RP. This correlation shows that the type of labelling
bias, introduced by the labelling kit of choice, makes the
overall profile more alike suggesting that ULS labelling
of samples will result in a comparable profile of other
ULS samples while the FFPE-RP kit will have its own
bias and similar profiles for comparison between differ-
ent samples. In contrast to this, the influence of sample
storage (FPPE vs frozen) was stronger than the influence
of labelling kit used (FFPE-RP or frozen-RP vs ULS) as
we observed better correlation between the independent
labelling reaction (ULS, FFPE-RP) than between the fro-
zen RP and FFPE-RP labelling reaction (Figure 2A).
Poor correlations and corresponding array profiles
were seen for samples with very low amounts of DNA
irrespective of labelling reactions (Figure 2E and samples
9, 11, 15 and 18 in Table 2). For these reactions a mini-
mum of 50 to 100 ng DNA was used. These results
indicate the possible presence of substances influencing
the efficiency of both the chemical and enzymatic label-
ling reactions. Because of the poor array performance
using very low DNA concentrations (samples 9, 11, 15
and 18), five other samples with similarly low DNA con-
centrations (samples 4, 5, 6, 7, and 8) were not tested as
indicated in Table 2.
For sample nr 2 and nr 17 the Pearson correlation
coefficient varied between 0.704 and 0.476 (Figure 2C
and 2D), respectively. Despite the weaker correlation for
case 17, both arrays showed similar profiles and similar
gains and losses were detected.
Interphase FISH
In two different samples, we readily detected a high level
of amplification of the MYC locus and a homozygous
deletion of the CDKN2A/CDKN2B loci with estimated
sizes of 0.7 Mb and 0.6 Mb, respectively (Figure 4A, C).
The two-colour Interphase FISH performed on dFFPE
tissue sections of case 26 showed a significant increase
of signal involving BAC-clone RP1-80K22 on one chro-
mosome arm only (Figure 4B). This pattern is compati-
ble with the amplification of the MYC locus as was












1 p36.33 - p33 749422 46786807 1053 + + + +
1 p12 - q23.3 119416284 160645328 539 + NC** + +
2 q33.2 - q37.3 204593489 242169652 575 - + + NC**
4 p16.3 - q13.3 146653 70631034 683 + + + +
5 p15.33 - q35.3 1163403 180617248 2104 + + + +
6 p22.1 - p21.1 26128906 44328148 558 + NC** + +
7 p22.3 - q36.3 289341 158602640 2056 + + + +
9 p24.3 - p13.3 322256 33155616 370 - + + +
9 q33.3 - q34.3 129159725 140128884 293 + NC** + +
10 p15.3 - q26.3 138006 135222624 1739 - + + +
11 p15.4 - q25 2906039 133951511 2213 + + + +
12 q13.11 - q14.1 47340134 56637091 379 + + + +
14 q11.2 - q32.33 19508645 106330010 1394 + + + +
15 q25.3 - q26.1 86577905 91761128 104 + + + +
16 p13.3 - q24.3 36566 88572953 1741 + + + +
17 p13.3 - q25.3 295150 78154619 2163 + + + +
18 p11.32 - q23 170029 76083258 875 + + + +
19 p13.3 - q13.43 231880 63389940 2096 + + + +
20 p13 - q13.33 73854 62363774 1115 + + + +
21 p11.1 - q22.3 10013063 46646924 549 + + + +
22 q11.1 - q13.33 14433273 49525271 833 + + + +
22 q13.1 37688858 37715585 3 - + NC** +
* according to NCBI hg18.
** NC: not called.
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Figure 4 Detection of small aberrations in MYC and CDKN2A/CDKN2B loci. A: Array-CGH showed a high level of amplification. The amplified
region of was about 700 kb in size involving the MYC locus on the long arm of chromosome 8. Arrows point out an enlargement of the MYC
locus. B: Interphase FISH verification using chromosome 8 centromere specific probe (green) and MYC locus specific BAC probe (red) on the
corresponding dFFPE section. The red arrow indicates signals of the amplified MYC locus and white arrow points to the normal locus. C: Array-
CGH result of a case with homozygous deletion. The estimated size of the homozygous deleted area was about 600 kb involving the CDKN2A/
CDKN2B loci on the short arm of chromosome 9. Arrows point out the region of the homozygous deletion, containing the CDKN2A/CDKN2B loci.
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detected by the array-CGH test using the corresponding
dFFPE tissue isolated DNA.
Discussion
We have established and successfully applied a robust
protocol to study heavily degraded DNA, obtained from
decalcified FFPE samples, collected from various institu-
tions using an oligonucleotide-based chip platform.
Both formic acid based decalcification and fixation
with non-buffered formalin solution similarly degrade
tissue DNA. As the average fragment length of the DNA
obtained from these samples is often less than 200 bps,
these are regarded as unsuited for further molecular
DNA testing [4,5,9].
In this study we used oligonucleotide based array
chips containing reporter elements of ~60 bps. For opti-
mal hybridisation the fragment length of the labelled
DNA sample should be similar in size as the reporter
elements (60-150 bps) [3]. Because enzymatic labelling
is introducing further fragmentation during labelling, we
applied the Universal Linkage System (ULS) labelling
technology, which is a direct chemical labelling, without
introducing further fragmentation [9,10]. In addition, we
compared the ULS labelling system to a commercially
available random primer (RP) labelling kit especially
developed for FFPE tissue derived DNA.
The overall reproducibility of the two FFPE labelling
systems tested was excellent (Figure 2). With both kits
we were able to obtain good results using 500 ng of
starting material in contrast to the 1 μg DNA recom-
mended by the vendors. The RP labelling has the benefit
of amplifying the samples during the labelling reaction.
By using as little as 150 ng degraded dFFPE DNA tem-
plate for the reaction, we obtained similar results to
using 500 ng (Figure 2B). However, further reduction of
the starting material, especially in cases with discrepan-
cies between estimated DNA concentrations in different
measuring methods, resulted in poor results. The use of
less than 500 ng DNA for ULS labelling resulted in too
weak signals and is therefore not recommended.
Samples labelled with the RP kit showed higher fluor-
escence intensities after scanning as compared to the
ULS labelled samples. However, the overall variance of
the log2 ratio distribution of the signal was higher as
compared to the ULS system (Figure 3A, B). For one
case (Nr 10), we had access to both frozen and dFFPE
samples. By comparing three kinds of labelling systems
a good correlation was observed between all labelling
systems and samples (Figure 3, Table 3).
We showed that, irrespective of the fragment size of the
DNA, all samples with sufficient quantity were eligible for
testing. Since correctly estimated DNA concentration is
more critical for successful testing than the quality of the
DNA (i.e. fragment size), DNA concentrations were
established by using two independent approaches. For
some samples we observed discrepancies between the
absorption-based DNA concentration measurement and
the estimation based on ethidium bromide stained gel ima-
ging. In general, the absorption based system tends to
overestimate the final DNA yield resulting in a suboptimal
amount for testing (Figure 1). This observed difference
might, in part, be explained by the presence of negatively
charged matrix glycoproteins such as chondroitin 4-sul-
phate, chondroitin 6-sulphate and keratan sulphate in
some of the tumour samples. Some of these matrix glyco-
proteins may have similar charges as DNA and conse-
quently could bind to the purification columns when the
total DNA content of the sample was low. None of the
used labelling systems gave reliable array profiles in cases
with high over estimates of concentration. In these cases,
in addition to the low DNA concentration, other factors
might interfere with the labelling reaction and could be
responsible for the failure.
The low amount of DNA might be compensated for
by a whole genome amplification step using DOP-PCR,
GenomePlex or Phi29 polymerase based reactions. How-
ever, it has been shown by others that when using good
quality FFPE samples, DOP-PCR results in amplification
biases and GenomePlex was suitable in only 58% of the
analysed cases [9,11]. The use of multiplex PCR based
pre-screening of FFPE samples may be used to select
samples, however, it is noteworthy that most of our
samples were degraded beyond the exclusion limits of
those QC reactions and would not provide a good pre-
diction [4,5,9]. There are several reports using FFPE
samples for genomic profiling either on BAC array [4],
oligonucleotide based array or the Illumina Golden Gate
SNP array systems [6,12,13]. The Golden Gate system
has a relatively low resolution consisting of approxi-
mately 6000 SNP reporter elements with an average
physical distance of about 500 kb. Due to the increased
variation of signal ratio values, extensive smoothing
steps (i.e. averaging of multiple probes for a given seg-
ment) are routinely applied to even out these variations.
In turn, the overall resolution of these platforms
decreases and most of the changes reported will concern
whole chromosome arms or chromosome regions over
at least 15-20 Mb in size. In contrast to these limita-
tions, the procedure we established readily detected
both homozygous deletions and high level of amplifica-
tions of 0.6 and 0.7 Mb in size, respectively (Figure 4).
Conclusions
We developed a reliable DNA isolation and labelling
procedure using decalcified, formalin-fixed, paraffin-
embedded tissue from various clinical specimens. Using
two independent techniques (gel-based and absorption-
based), we showed that the estimation of DNA
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http://www.biomedcentral.com/1756-0500/4/1
Page 10 of 11
concentration is a more critical step in sample quality
assessment than DNA quality (assessed by the degree of
fragmentation). In our assessment, both the direct-
chemical-labelling-based ULS kit and the modified
random-prime labelling kit worked equally well.
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